Pertuzumab: Optimizing HER2 Blockade
نویسندگان
چکیده
منابع مشابه
Pertuzumab: optimizing HER2 blockade.
Pertuzumab has been approved by the U.S. Food and Drug Administration for use in combination with trastuzumab and docetaxel for the first-line treatment of patients with advanced HER2-positive (HER2(+)) breast cancer. Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2 and inhibits heterodimerization of HER2 with other HER fam...
متن کاملDual HER2 Blockade.
a Department of Gynecology, Martin-Luther-University, Halle/Saale, Germany; b Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; c Peter MacCallum Cancer Centre, Melbourne, Australia; d Department of Oncology and Radiotherapy, Medical University of Gda ’ nsk; Gdansk, Poland; e Helen Diller Family Comprehensive Cancer Center, Univers...
متن کاملPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
BACKGROUND In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the me...
متن کاملPertuzumab in the treatment of HER2+ breast cancer.
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family. It has a unique and complimentary mechanism of action compared with trastuzumab, and the combination has resulted in the enhanced blockade of the HER signaling pathway. When pertuzumab was used in combin...
متن کاملPertuzumab: new hope for patients with HER2-positive breast cancer.
BACKGROUND Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurred since trastuzumab therapy was introduced into daily clinical practice. However, because trastuzumab resistance is common, new molecules with complementary and/or synergisti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2013
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-13-0518